Abstract

Methods and systems for performing secure quantum key distribution (QKD) over noisy channels are disclosed. A first computing device generates a challenge set using a secret seed, applies the challenges to its CRP, and receives an ordered set n responses, where n has the same number of bits as the key. It then sends only those responses in positions that correspond to is in the key to the second computing device. Those responses are sent under a QKD protocol such as BB84. The second computing device generates the same challenges and recovers the same responses with a mirror CRP mechanism. It also receives the subset of responses from the first computing device. Generated responses that match received responses correspond to is in the key, and Os are assigned to all other positions.

IPC Classes  ?

• H04L 9/08 - Key distribution

Goods & Services

Providing grants for undergraduate student internships

Goods & Services

Educational services, namely, providing workshops, seminars, internships, professional development, mentoring and leadership training programs for students, administrative professionals and faculty in the pursuit of research opportunities or research careers in academia, business and the public sector, including distribution of related course materials; providing educational information on-line relating to research internships and mentoring programs in all academic fields for students; membership club services, namely, for promotion of mentoring programs for students in academia, business and the public sector.

Goods & Services

Educational services, namely, providing workshops, seminars, internships, professional development, mentoring and leadership training programs for students, administrative professionals and faculty in the pursuit of research opportunities or research careers in academia, business and the public sector, including distribution of related course materials; providing educational information on-line relating to research internships and mentoring programs in all academic fields for students; membership club services, namely, for promotion of mentoring programs for students in academia, business and the public sector.

Goods & Services

Providing grants for undergraduate student internships

Abstract

A system includes a high density surface emitting laser array source, the high density surface emitting laser array source comprising a near infrared vertical cavity semiconductor laser (VCSEL) array that enables individual access to closely packed laser elements on a sub-microsecond timescale, a detector comprising a dynamic vision sensor having low latency, high dynamic range and ultralow power, and a chip scale neuromorphic computing platform configured to perform real-time target image reconstruction, the distinctly separate high density surface emitting laser array source, the detector and the chip scale neuromorphic computing platform integrated into a single functional whole.

IPC Classes  ?

• H04N 23/95 - Computational photography systems, e.g. light-field imaging systems
• G06N 3/049 - Temporal neural networks, e.g. delay elements, oscillating neurons or pulsed inputs
• H04N 25/47 - Image sensors with pixel address outputEvent-driven image sensorsSelection of pixels to be read out based on image data

Abstract

The present disclosure describes a method of inhibiting lithium dendrite penetration through a lithium-based solid electrolyte by providing the lithium-based solid electrolyte with an interlayer of reduced Graphene Oxide. The present disclosure also describes a lithium-based solid electrolyte with an interlayer of reduced Graphene Oxide.

IPC Classes  ?

• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0562 - Solid materials

Abstract

The present disclosure describes a method of providing residual compressive stress to a lithium-based solid electrolyte by ion exchanging lithium ions with ions having a larger ionic radius that the lithium ions.

IPC Classes  ?

• H01M 10/0562 - Solid materials
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium

Abstract

Provided herein are nitrophenyl-acrylamide compounds, their preparation, and uses thereof.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/4245 - Oxadiazoles
• A61K 31/4402 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 35/00 - Antineoplastic agents
• C07C 255/23 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
• C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 207/09 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 207/27 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
• C07D 207/273 - 2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
• C07D 213/30 - Oxygen atoms
• C07D 233/40 - Two or more oxygen atoms
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 295/125 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
• C07D 307/22 - Nitrogen atoms not forming part of a nitro radical
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention is directed to methods for inhibiting growth of bacteria and to nanometer scale surfaces having antibacterial properties.

IPC Classes  ?

• B44C 1/22 - Removing surface-material, e.g. by engraving, by etching
• A61M 16/04 - Tracheal tubes
• C12N 1/36 - Adaptation or attenuation of cells
• C12N 11/00 - Carrier-bound or immobilised enzymesCarrier-bound or immobilised microbial cellsPreparation thereof
• C23F 1/14 - Aqueous compositions

Abstract

The present invention discloses a method for preventing or treating atrial fibrillation (AF) in a subject by administering a therapeutically effective amount of a flavonol compound (Formula 1 or a tautomer thereof), a pharmaceutically acceptable salt, hydrate, or solvate thereof. The method involves obtaining a subject in need of AF prevention or treatment, suspected to require such prevention or treatment, or a normal healthy subject, and administering the compound to the subject Formula 1 comprises specific atoms and substituents, including - H, -OCH3, -OH, -I, -Br, -F, or Cl. By utilizing the flavonol compound of Formula 1, the risk of AF development or the prevalence of AF in the subject is reduced, providing an effective approach for managing AF in individuals.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/12 - Ketones
• A61K 31/33 - Heterocyclic compounds

Abstract

An immune suppressor cell modified to include an innate immune effector is described. Methods of using the modified immune suppressor cell to treat cancer are also described.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A catalytic compound of formula I, II, or III is described; wherein M is selected from the group consisting of Y, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu; R1, N is an integer from 1 to 3; R2, R3, and R4 are independently selected from lower alkyl, lower alkoxy, C5-C8 aryl, and NR62, wherein R6 is —CH3 or —C2H5; and R5 is selected from —H, lower alkyl, lower alkoxy, and benzylic. Methods of using the compound to catalyze the formation of polylactides, and polylactides prepared using these methods are also described.

IPC Classes  ?

• C08G 63/82 - Preparation processes characterised by the catalyst used
• C08G 63/08 - Lactones or lactides

Abstract

Described herein are methods and devices directed to preparing complex tissue samples for direct single cell analysis (e.g., scRNAseq) in a comprehensive, enzyme-free manner. The device and method use shear forces, mechanical features, electrical treatment, and acoustics, in addition to programmed microfluidic flow to dissociate a tissue sample into a purified suspension of single cells. In an example, a tissue sample is loaded into a well with retaining mesh on either side. A combination of microfluidic flow, shear, and electrical treatment elutes clumps (e.g., aggregates or agglomerates) of cells from this well, while a sample-specific, back and forth flow is repeated to begin an impurity removal process. At an outlet of the device, purified cells suitable for single cell analysis are eluted. As described herein, the device can be operated continuously.

IPC Classes  ?

• G01N 1/31 - Apparatus therefor
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

Systems and methods are provided for using a stabilized time-reversal symmetry breaking field to provide a desired function. A structure includes a layer of a first material positioned in contact with a layer of a second material to form an interface between the first material and the second material. Each of the first material and the second material are selected such that a time-reversal symmetry breaking field associated with the interface is stabilized. A control apparatus associated with the structure is configured to control a ferromagnetic state associated with the interface.

IPC Classes  ?

• H10N 60/10 - Junction-based devices
• H10N 60/01 - Manufacture or treatment
• H10N 60/85 - Superconducting active materials

Abstract

The present disclosure provides, for instance, a method of treating oligodendroglial dysfunction including Angelman Syndrome and autism spectrum disorder, the method comprising administering to the subject a non-steroidal selective estrogen receptor beta agonist, thereby treating the oligodendroglial dysfunction in the subject.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention provides the uses of chemical waste and byproducts in a chemical library to store digital information, and methods for computing with unknown waste chemicals by encoding digital data into a plurality of chemicals to obtain a dataset; translating the dataset into a chemical form; reading the data set; querying the dataset by performing an operation to obtain a perceptron; and analyzing the perceptron for identifying change in at least one of the chemicals, thereby developing a chemical computational language. The invention demonstrates a workflow for representing abstract data in synthetic metabolomes. Also presented are several demonstrations of kilobyte-scale image data sets stored in synthetic metabolomes, recovered at >99% accuracy.

IPC Classes  ?

• G06N 99/00 - Subject matter not provided for in other groups of this subclass

Abstract

A method includes providing an ensemble of distributed sensors, delivering radio frequency (RF) power to each sensor by inductive near-field coupling by a magnetic field projected by an epidermal transmit (Tx) coil, in each individual sensor, detecting a sparse binary event in its immediate environment, reporting the detected sparse binary event to an external RF receiver hub asynchronously and with low latency, and minimizing error rates due to statistical data packet collisions in asynchronous telemetry by digitally encoding each sensor according to a particular address scheme where each address is one function from an infinite set of mathematically orthogonal functions, enabling a simultaneous detection from up to ten thousand points without interference at a common receiver.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• H04L 1/00 - Arrangements for detecting or preventing errors in the information received
• H04L 27/20 - Modulator circuitsTransmitter circuits
• H04W 74/08 - Non-scheduled access, e.g. ALOHA
• H04W 84/18 - Self-organising networks, e.g. ad hoc networks or sensor networks

Abstract

An electronic device and method for object-centric video representation for action prediction is provided. The electronic device extracts a first sequence of video segments from video content associated with a domain and detects a set of objects in the first sequence of video segments. The electronic device generates a set of embeddings based on the first sequence of video segments and the set of objects. The electronic device applies a PTE model on the set of embeddings. The electronic device predicts, based on the application, a set of object-action pairs associated with a second sequence of video segments of the video content. Each object-action pair includes an action to be executed using an object of the set of objects in a video segment of the second sequence of video segments. The second sequence of video segments succeeds the first sequence of video segments in a timeline of the video content.

IPC Classes  ?

• G06V 20/40 - ScenesScene-specific elements in video content
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding
• G06V 40/20 - Movements or behaviour, e.g. gesture recognition

Abstract

An electronic device and method for using neural language models for long-term action anticipation from videos is provided. The electronic device receives a video that includes one or more objects performing a physical task and generates, based on the video, a first set of tags that corresponds to a first sequence of actions associated with the physical task. The electronic device generates a first prompt for a neural language model based on the first set of tags and predicts, by application of the neural language model on the first prompt, a second set of tags that corresponds to a second sequence of actions associated with the physical task. The second sequence of actions succeeds the first sequence of actions. The electronic device controls a display device to display first prediction information based on the second set of tags.

IPC Classes  ?

• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 20/40 - ScenesScene-specific elements in video content

Abstract

A cardiovascular variability parameter can be detected independent of the relative absorption contribution of melanin in biological tissue. A light source and a polarization shaping device can illuminate a biological tissue with a polarized light having an inhomogeneous optical polarization wavefront. A polarization analyzer can receive the polarized light after it has interacted with the biological tissue and output a first and second polarization state. A detection device can have a light detector for detecting the first and second polarization state and at least a processor for detecting data related to the first and second polarization states, determining relative absorptions contributions of superficial and deep components of the biological tissue based on the first and second polarization states, and determining the cardiovascular variability parameter based on the relative absorption contributions of the superficial and deep components.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/026 - Measuring blood flow
• A61B 5/08 - Measuring devices for evaluating the respiratory organs

Abstract

The present disclosure provides, for instance, a method of inhibiting resistance to a DDR inhibitor in a subject, the method comprising administering to the subject a GDF15 inhibitor, thereby inhibiting resistance to the DDR inhibitor in the subject. The disclosure also provides combination therapies for cancer, comprising co-administration of a DDR inhibitor and a GDF15 inhibitor.

IPC Classes  ?

• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

Described herein are lifesaving compositions and methods including the administration of alpha-2 (α2) adrenergic antagonists as a drug class for use in the reversal of substance overdose that can be contributed to by xylazine and xylazine congeners, alcohol, fentanyl/opioids, and benzodiazepines in humans. In some instances, the substance overdoses can appear to be opioid induced but are not responsive to administration of therapeutic agents (e.g., Naloxone administration). The antagonists can be safely and quickly produced using yohimbine, and the compositions and methods are operative to address the United States' national crisis of human overdoses caused by combining various illicit (street) drugs with xylazine.

IPC Classes  ?

• A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 39/02 - Antidotes

Abstract

A system for 3D and 4D capture comprises a stage including a multi-sided stage frame and frame defining a stage capture volume with a plurality of first sensor modules supported by frame. Each first sensor modules include a module frame with a translucent front panel attached to which is mounted an RGB camera, a depth camera, an IR camera and a microphone, and a back panel attached to the opposite side of the module frame from the front panel, the back panel supporting a lighting array. The stage further comprises a plurality of second sensor modules mounted that include an elongated frame having a translucent elongated front panel attached to said front side of said elongated frame, that supports at least one RGB camera.

IPC Classes  ?

• G06T 7/593 - Depth or shape recovery from multiple images from stereo images

Abstract

The invention provides a highly versatile system to promote vascularization in ischemic tissue. The system is composed of a fully defined, customizable hydrogel loaded with a potent cocktail of proangiogenic growth factors. The hydrogel's mechanical, degradation, and factor release behavior can be tailored to the specifications of any given target tissue or ischemic disease state. The growth factor cocktail can be optimized for maximal vessel density or size to meet the perfusion specifications required by the tissue. The embodiments of the disclosure concern methods and compositions of the system, with examples of preparation for both injectable and implantable delivery modes.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/30 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein

Abstract

A system and method are provided to improve physiological function in a patient having a spinal cord lesion or quantify the state of the spinal cord and thus the state of progression of the spinal cord lesion. The system and method use spinal electrophysiological data, such as ECAPs, to determine a patient's physiological state and direct delivery of spinal cord stimulation in response to the determination of the patient's physiological state to achieve a therapeutic effect.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/02 - ElectrotherapyCircuits therefor Details
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/378 - Electrical supply
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

III-nitride-based hot electron transistors (HETs) offer significant promise as high-speed, high-power devices, but their performance has been limited to below that of competing technologies. A HET with collector current density >440 kA/cm2 and common-emitter current gain >75 is disclosed. Polarization engineering of the emitter stack was used to allow for high-current collimated electron injection from the emitter with relatively low turn-on voltage. The use of only polarization charge in the undoped 10 nm-thick base allowed for high gain, through minimization of scattering, with atomic layer etching contact fabrication used to lower base access resistance.

IPC Classes  ?

• H01L 29/778 - Field-effect transistors with two-dimensional charge carrier gas channel, e.g. HEMT
• H01L 29/08 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions with semiconductor regions connected to an electrode carrying current to be rectified, amplified, or switched and such electrode being part of a semiconductor device which comprises three or more electrodes
• H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds

Abstract

Disclosed herein is a pattern recognition and feature extraction system and method configured to detect and analyze non-stationary, transient, or locally structured signals from longer time-series data of obtained beta waveforms of an animal to characterize a biomarker of a brain state or condition. An example system comprises a computing device configured to process obtained recordings of electrical activity arising from a brain of an animal for detecting beta wave events. A first representation of short-time segments may be generated to represent amplitude fluctuations indicating extrema and time-domain features in the beta wave events and a second representation for identifying temporal positions of the extrema in the first representation. The computing device compares statistical distributions of feature characteristics and generates mean waveforms of signals from at least one condition aligned by the temporal positions assigned to one of extracted feature types to indicate a brain state of the animal.

IPC Classes  ?

• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/384 - Recording apparatus or displays specially adapted therefor

Abstract

A multi-frequency wireless access device including a first waveguide having a pair of parallel metal plates with open sides and a slot in one of the metal plates, the slot permitting radiation to leak out, the leaked radiation illuminating a range of angles depending on frequency.

IPC Classes  ?

• H01Q 13/22 - Longitudinal slot in boundary wall of waveguide or transmission line
• H01Q 1/22 - SupportsMounting means by structural association with other equipment or articles
• H01Q 21/28 - Combinations of substantially independent non-interacting antenna units or systems

Abstract

The present disclosure provides methods for enhancing the uptake of a chemotherapeutic agent into a brain tumor in a subject by administering indirubin, or a derivative thereof, with a therapeutically effective amount of a chemotherapeutic agent.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 33/243 - PlatinumCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure generally relates to systems and methods for analysis of peptide photodissociation for single-molecule protein sequencing. In one aspect, systems and methods are directed to allowing one to fragment a single protein molecule in aqueous solution so that its composition and sequence of amino acids can be measured by mass spectrometry. This may be useful for single-molecule protein sequencing technology.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• G01N 33/487 - Physical analysis of biological material of liquid biological material
• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

A method of making and using nanoparticles that target biofilm are provided.

IPC Classes  ?

• A61K 33/38 - SilverCompounds thereof
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 31/04 - Antibacterial agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C12N 9/22 - Ribonucleases
• A61K 38/46 - Hydrolases (3)

Abstract

The invention provides molecular tools to visualize, isolate, and manipulate the glial cells that are necessary for the formation, stability, and function of the synapse. The inventors identified a unique gene expression signature that distinguishes perisynaptic Schwann cells from all other Schwann cells. Using a combinatorial approach and coëxpressing two different fluorescence proteins, each using a different promoter, only those glial cells associated with the neuromuscular synapse are labeled.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
• G01N 15/1434 - Optical arrangements
• G01N 15/149 - Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

An artificial intelligence (AI) and machine learning (ML) based graphical user interface (GUI) system for early detection of depression symptoms using facial expression recognition and electroencephalogram is provided via receiving image data of a biological subject under examination for depression; receiving, from the biological subject, electroencephalogram data; analyzing the image data, via a first machine learning model, to identify an emotional state conveyed by a face of the biological subject; analyzing the electroencephalogram data, via a second machine learning model, to identify a severity level of depression in the biological subject; and providing the emotional state identified by the first machine learning model and the severity level identified by the second machine learning model to a graphical user interface.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/372 - Analysis of electroencephalograms
• G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding
• G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Methods for the encoding an encryption key for secure storage are disclosed. The methods rely on the use of unclonable, one-way functions, such as images of biological objects that may be measured according to challenges to result in responses. A biometric print of a biological object is measured with a set of n challenges resulting in n responses. The responses are an ordered sequence, with each response having a fixed position in the sequence. A key is generated of bit length n. A subset of m responses in the full set of n responses is selected, where the selected responses correspond to positions of is in the key. The response subset is stored. The key is then used, and deleted. A party wishing to re-generate the key generates the same set of challenges, measures the same biological object with the challenges a second time, and generates a second set of n responses. Responses in the stored subset of m responses will match responses in the second set of n responses at certain positions in second set of n responses. These matching positions correspond to is in the key. The non-matching positions correspond to Os. Thus, comparison between the response sets recovers the key.

IPC Classes  ?

• H04L 9/08 - Key distribution
• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system

Abstract

Artificial intelligence-assisted gait analysis of Christianson syndrome patients is provided via recording video of a subject performing a walking task; analyzing the video to determine poses and relationships between a plurality of points of the subject corresponding to anatomical features of the subject while performing the walking task; analyzing, using a machine learning model, a gait of the subject based on the relationships between the plurality of points while performing the walking task; classifying, using the machine learning model, the subject as exhibiting or not exhibiting symptoms of a motor disorder based on the gait; and outputting, via a graphical user interface, a determination of the subject as exhibiting or not exhibiting the symptoms of the motor disorder.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/70 - Determining position or orientation of objects or cameras
• G06V 10/34 - Smoothing or thinning of the patternMorphological operationsSkeletonisation
• G06V 40/20 - Movements or behaviour, e.g. gesture recognition
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Systems and methods for training a machine learning model for non-destructive evaluation. A plurality of training samples are generated, with a subset of the plurality of training samples representing an article with a defect or a combination of defects. Training samples are generated by generating a virtual model of the article with defect at a computer system, generating a simulated signal representing an output of a non-destructive evaluation system scanning the physical article using the virtual model at the computer system, and associating a representation of the simulated signal with parameters representing a characteristic of the virtual model of the article with defects. The machine learning model is trained on the plurality of training samples. The trained machine learning model is applied on to measurements collected from physical articles to characterize or quantify defects.

IPC Classes  ?

• G01N 29/44 - Processing the detected response signal
• G01N 29/06 - Visualisation of the interior, e.g. acoustic microscopy
• G06N 3/08 - Learning methods

Abstract

Chemical syntheses for producing new Yariv reagent compositions with improved functions, fluorescence, and chromophores are disclosed herein. The new compositions are shown to expand the studies of arabinogalactan proteins (AGPs), galactans, and glycoproteins to a wider variety of samples, including fresh samples of tissues, and to provide additional benefits. The compositions and methods enable previously unobtainable studies in plant tissue staining and imaging including highly specific binding of AGPs, providing higher signal to noise, better limits of detection, and high specificity for targeted AGPs.

IPC Classes  ?

• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Safe lifting devices configured for lifting of a fallen patient from a surface and for a transport of the patient are disclosed herein. The devices comprise a class 1 lever including two larger wheels disposed about parallel at a fulcrum of the lever with each of the two larger wheels having shorter load leverage arms and longer effort leverage arms extending radially outward and defining a lever angle of greater than 90°. Each of the larger wheels disposed at the fulcrum includes a smaller rolling wheel attached to each larger wheel by an axle and a medium rolling wheel attached to each larger wheel by a different axle. When an operator pulls down the longer effort leverage arms the patient is safely lifted.

IPC Classes  ?

• A61G 7/10 - Devices for lifting patients or disabled persons, e.g. special adaptations of hoists thereto
• A61G 5/14 - Standing-up or sitting-down aids

Abstract

The present disclosure provides, for instance, a method of treating neuroinflammation including NMOSD in a subject, the method comprising administering to the subject a CRTH2 antagonist, thereby treating the neuroinflammation in the subject.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 37/02 - Immunomodulators

Abstract

A method of treating heart failure and/or a stroke in a subject in need thereof is provided. The method includes administering a therapeutically effective amount of a compound that upregulates HIF-1α transcriptional activity.

IPC Classes  ?

• C07D 231/22 - One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
• C07D 207/32 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 231/26 - 1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
• C07D 307/36 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
• A61P 9/02 - Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Described are improved therapies for the treatment of cancer including prostate cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 37/04 - Immunostimulants

Abstract

Embodiments described herein are directed to compounds and methods for generating hydrogen persulfide. In particular, the disclosure provides compounds including a stable sulfine moiety which reacts with hydrogen sulfide, such as at a site within an individual, and ultimately generates hydrogen persulfide, such as in vivo within the individual.

IPC Classes  ?

• C01B 3/56 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification by contacting with solidsRegeneration of used solids
• C01B 17/18 - Hydrogen polysulfides
• C01B 17/16 - Hydrogen sulfides
• C01B 17/04 - Preparation of sulfurPurification from gaseous sulfur compounds including gaseous sulfides
• C01B 3/02 - Production of hydrogen or of gaseous mixtures containing hydrogen

Abstract

A method of treating urinary tract cancer in a subject in need thereof is described. The method includes determining if there are loss-of-function mutations in the CDKN1A and RB1 genes in a biological sample from the subject; and treating the subject with a combination of a checkpoint kinase inhibitor and a DNA damaging agent if there are loss-of-function mutations in the CDKN1A and RB1 genes. Alternately, the method includes determining if there is a loss-of-function mutations in a CDKN1A gene in a biological sample from the subject; determining if there is a mutation in a second gene selected from the list consisting of RAB44, TERT, MUC16, HRNR, and FLG; and selecting specific anticancer treatment for the subject based on the identification of a mutation in the second gene.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 33/243 - PlatinumCompounds thereof
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Neurofeedback training can include a subject visualizing a mental image, neural signals that quantify visual working memory related to the mental image can be recorded using scalp electrodes. The subject's performance with the visualization can be scored based on neural activity related to a cognitive function within the neural signals during an induction period. Feedback can be provided to the subject based on the scoring to inform the subject of a success rate related to the visual working memory. The goal of the neurofeedback training can be to improve the subject's cognitive function.

IPC Classes  ?

• A61B 5/375 - Electroencephalography [EEG] using biofeedback
• A61B 5/378 - Visual stimuli
• A61B 5/384 - Recording apparatus or displays specially adapted therefor

Abstract

A system and method of operating a mobile robot to perform tasks includes representing a task in an Object-Oriented Partially Observable Markov Decision Process model having at least one belief pertaining to a state and at least one observation space within an environment, wherein the state is represented in terms of classes and objects and each object has at least one attribute and a semantic label. The method further includes receiving a language command identifying a target object and a location corresponding to the target object, updating the belief associated with the target object based on the language command, driving the mobile robot to the observation space identified in the updated belief, searching the updated observation space for each instance of the target object, and providing notification upon completing the task. In an embodiment, the task is a multi-object search task.

IPC Classes  ?

• B25J 9/16 - Programme controls
• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks

Abstract

Provided herein are compositions and methods useful in treating diseases such as ALS and FTD. Disclosed compositions and methods can prevent protein aggregation, particularly with regard to RNA-binding proteins.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Immune checkpoint blockade (ICB) therapy has provided hope for treating various cancers. However, many tumors are resistant to ICB. Described herein are lifesaving compositions and anti-cancer methods including the administration of combination therapies of a small molecule GSK-3 inhibitor and a therapeutic agent effective for an immune checkpoint blockade (ICB) therapy to a subject in need thereof. In some aspects, the cancer response the the GSK-3 inhibitor can be utilized to guide the ICB therapy. In particular, tumors that are resistant to ICB are compromised by the GSK-3 inhibitor and become vulnerable to the combination therapies disclosed herein.

IPC Classes  ?

• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A system includes an array of chemical, pressure, and temperature sensors, and a temporal airflow modulator configured to provide sniffed vapors in a temporally-modulated sequence through a plurality of different air paths across multiple sensor locations.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• B81B 3/00 - Devices comprising flexible or deformable elements, e.g. comprising elastic tongues or membranes

Abstract

Instances of a single brain computer interface (BCI) system can be implemented on multiple devices. An active instance can control the associated device. The instances can each communicate with a neural decoding system that can receive neural signals from a user, process the neural signals, and output a command based on the processed neural signals. A device running the active instance of can be in communication with the neural decoding system to receive a command. The device can include a display, a non-transitory memory storing instructions, and a processor to execute the instructions to: run an instance of a control program; and execute the task based on the command.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

Systems and methods are provided that exploit local dynamics of a skyrmion to perform a computing function. A magnetic system hosts a skyrmion that transitions among a plurality of states, with each of the plurality of states having an associated switching probability. A bias source provides energy to the magnetic system as to adjust a switching probability associated with one of the plurality of states. A readout component measures a state of the skyrmion.

IPC Classes  ?

• H01F 10/32 - Spin-exchange-coupled multilayers, e.g. nanostructured superlattices
• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
• G11C 11/18 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using Hall-effect devices

Abstract

A method of treating or preventing a neurodegenerative disease or disorder such as Alzheimer's disease, or Down syndrome is described. The method includes administering a therapeutically effective amount of a CsA-type drug and/or an INDY-type to a subject in need thereof. Methods of identifying a neuromodulating drug using zebrafish larvae are also described.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/18 - Sulfonamides
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/433 - Thiadiazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine

Abstract

Described herein are methods and systems for preventing a glycemic event. One or more improved deep-learning models for predicting glycemic events may receive current blood glucose data and other physiological data from associated with a patient. The one or more models may determine one or more future blood glucose values and whether or not the one or more future blood glucose values satisfy one ore more thresholds associated with one or more glycemic events (e.g., hypoglycemia and/or hyperglycemia). If the one or more future blood glucose values satisfy the one or more thresholds, one or more actions may be taken (e.g., administration of insulin).

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Abstract

A method for scanning near-field optical microscopy comprises illuminating an apertureless atomic force microscopy (AFM) probe with electromagnetic energy having a frequency in the Terahertz range, where the sample under observation includes a dielectric layer having a thickness greater than the radius of the tip of the AFM probe. A system for scanning near-field optical microscopy comprises a collimated light source for emitting collimated light, a photoconductive antenna for converting collimated light into electromagnetic energy having a frequency in the Terahertz range, an AFM probe, a sample comprising a dielectric layer, the dielectric layer having a thickness greater than the radius of the probe tip; and a detector configured to detect energy that has interacted with the sample.

IPC Classes  ?

• G01Q 60/06 - SNOM [Scanning Near-field Optical Microscopy] combined with AFM [Atomic Force Microscopy]
• G01Q 60/18 - SNOM [Scanning Near-Field Optical Microscopy] or apparatus therefor, e.g. SNOM probes
• G01Q 60/34 - Tapping mode
• G01N 21/3581 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared lightInvestigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using Terahertz radiation

Abstract

A method for scanning near-field optical microscopy comprises illuminating an apertureless atomic force microscopy (AFM) probe with electromagnetic energy having a frequency in the Terahertz range, where the sample under observation includes a dielectric layer having a thickness greater than the radius of the tip of the AFM probe. A system for scanning near-field optical microscopy comprises a collimated light source for emitting collimated light, a photoconductive antenna for converting collimated light into electromagnetic energy having a frequency in the Terahertz range, an AFM probe, a sample comprising a dielectric layer, the dielectric layer having a thickness greater than the radius of the probe tip; and a detector configured to detect energy that has interacted with the sample.

IPC Classes  ?

• G01Q 60/30 - Scanning potential microscopy
• B82Y 35/00 - Methods or apparatus for measurement or analysis of nanostructures
• G01Q 60/42 - Functionalisation

Abstract

Disclosed are methods for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one long interspersed nuclear element 1 (LINE-1, L1) endonuclease inhibitor (L1 EN inhibitor), either alone or in combination with at least one additional therapeutic agent. Effectiveness of the methods can be measured via biomarkers and/or by a decrease in symptoms compared to those symptoms before administration of the L1 EN inhibitor. Specific chemical structures of the L1 EN inhibitors are identified and shown herein.

IPC Classes  ?

• A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/4035 - Isoindoles, e.g. phthalimide
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 31/433 - Thiadiazoles
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/50 - PyridazinesHydrogenated pyridazines
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed is a method for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one reverse transcriptase inhibitor (RTI).

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure generally relates to mass spectrometers, including but not limited to mass spectrometers able to emit ions at determinable times. In some aspects, the time between when ions leave an ion source and the time the ions reach a detector may be determined at a relatively high time resolutions, which may be useful for certain applications such as sequencing of biopolymers. In addition, in some cases, a relatively high number of ions leaving an ion source may be determined at a detector, e.g., at least 50% or more of the ions that are produced. Other aspects are generally directed to systems and methods for using such mass spectrometers, techniques involving such mass spectrometers, or the like.

IPC Classes  ?

• H01J 49/42 - Stability-of-path spectrometers, e.g. monopole, quadrupole, multipole, farvitrons
• C12Q 1/6872 - Methods for sequencing involving mass spectrometry
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locksArrangements for external adjustment of electron- or ion-optical components
• H01J 49/16 - Ion sourcesIon guns using surface ionisation, e.g. field-, thermionic- or photo-emission
• H01J 49/22 - Electrostatic deflection
• H01J 49/24 - Vacuum systems, e.g. maintaining desired pressures

Abstract

Disclosed are methods for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one long interspersed nuclear element 1 (LINE-1, L1) endonuclease inhibitor (L1 EN inhibitor), either alone or in combination with at least one additional therapeutic agent. Effectiveness of the methods can be measured via biomarkers and/or by a decrease in symptoms compared to those symptoms before administration of the L1 EN inhibitor. Specific chemical structures of the L1 EN inhibitors are identified and shown herein.

IPC Classes  ?

• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention provides a method for optimizing the treatment of colorectal cancer in a subject comprising the steps of extracting colorectal cancer cells from the subject, determining the transcriptional response in colorectal cancer cells across four or more clinically used chemotherapeutic drugs in terms of gene identity, magnitude of change, and p53 dependence, and determining the gene signature to determine the optimal course of treatment for the subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/282 - Platinum compounds
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 33/243 - PlatinumCompounds thereof

Abstract

The invention provides for the use of metformin or other mitochondrial complex 1 inhibitors with fiber probiotics to treat gut dysbiosis, especially antibiotic-induced gut dysbiosis (AID).

IPC Classes  ?

• A61K 31/721 - Dextrans
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 31/717 - Celluloses
• A61K 31/732 - Pectin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The present invention provides to compositions and methods useful in the treatment of neurological disorders including, but not limited to, Angelman syndrome, depression, traumatic brain injury, stroke, and Alzheimer's disease. CN2097, a rationally designed cyclic peptidomimetic drug that has been demonstrated to have effectiveness in preclinical models for the treatment of neurological disorders, is rapidly cleared and has a short half-life. The present invention provides a stable analog of CN2097.

IPC Classes  ?

• C07K 7/52 - Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Although patients with EGFR mutant NSCLC frequently respond to initial therapy with tyrosine kinase inhibitors (TKIs), most then develop therapeutic resistance. It is demonstrated herein that: (i) CHI3L1 activates a pathway (the HIPPO/Yap/Taz pathway) that plays an important role in the pathogenesis of TKI resistance and can serve as a biomarker of EGFR mutant lung cancer progression; (ii) inhibitors of CHI3L1 block this therapeutic resistance and act as a therapeutic in EGFR mutant NSCLC; and (iii) CHI3L1 inhibitors can interact in a synergistic manner with TKI in the treatment of EGFR mutant NSCLC.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A laminated structure is prepared by providing a self-assembled monolayer between an ETL and an MHP layer, wherein the self-assembled monolayer is formed by a monomer having the formula halide-alkyl linker-anchor moiety.

IPC Classes  ?

• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 85/10 - Organic polymers or oligomers
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3

Goods & Services

recruitment and placement of personnel in the arts training of personnel in the arts

Abstract

Methods and compositions for increasing neurogenesis or muscle regeneration and for preventing or treating diseases, disorders or conditions associated with neurodegeneration or muscle regeneration, are provided herein.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• A01K 67/0276 - Knock-out vertebrates
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Compositions for generating cardiac tissue are provided. The compositions may improve cardiac tissue function.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/24 - Collagen
• A61L 27/52 - Hydrogels or hydrocolloids
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

A three degrees-of freedom robotic flapper includes a fuselage, the fuselage housing motors and driving trains, a left wing attached to the fuselage, and a right wing attached to the fuselage, the left wing and the right wing configured to perform a wing flapping motion, a wing twisting motion and a wing folding motion.

IPC Classes  ?

• B64C 33/02 - WingsActuating mechanisms therefor

Abstract

Closed-loop deep brain stimulation using neural and behavioral biomarkers of specific motor features is provided via training a machine learning model to differentiate first neural signals generated by a biological subject that are associated with tremor in the biological subject from second neural signals generated by the biological subject that are associated with bradykinesia in the biological subject; placing a first plurality and a second plurality of deep brain stimulation electrodes in a subthalamic nucleus (STN) of the biological subject; placing a plurality of microelectrodes and a plurality of macroelectrodes in the STN; in response to identifying, by the machine learning model, a given neural signal as one of the first or second neural signals, activating a corresponding one of the first or second plurality of electrodes with a therapeutically effective voltage and current to affect deep brain stimulation in the biological subject to treat a neuromotor disorder.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/388 - Nerve conduction study, e.g. detecting action potential of peripheral nerves

Abstract

Described herein are compositions and methods for treating P. falciparum malaria by specifically activating apoptosis in cells that express PfGARP without activating apoptosis in subject host cells or parasite cells that do not express PfGARP.

IPC Classes  ?

• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 33/06 - Antimalarials

Abstract

Methods and systems for estimating fluid flow characteristics are provided. In one embodiment, a method is provided that includes receiving a plurality of images of fluid flow at a plurality of times. The images may be analyzed with a machine learning model to predict one or more physical characteristics of the fluid flow, such as a velocity field, a pressure field, and/or a stress field. A loss measure may be calculated for the physical characteristics based on physical fluid flow constraints, boundary condition constraints, and/or data mismatch constraints. The machine learning model may be updated based on the loss value.

IPC Classes  ?

• G06T 7/20 - Analysis of motion
• G06T 7/00 - Image analysis

Abstract

Aspects of the invention are associated with the discovery of processes for converting methane (CH 4), present in a methane-containing feed that may be obtained from a variety of sources such as natural gas, to higher hydrocarbons (e.g., C2+ hydrocarbons) such as C2 hydrocarbons (e.g., ethane, ethylene, and acetylene) and aromatic hydrocarbons (e.g., benzene, one or more C1- or C2-substituted benzenes, and/or one or more fused ring aromatic hydrocarbons). Representative processes involve direct, non-oxidative methane conversion (NOMC), such that the need for an oxidant to form CO as an intermediate may advantageously be avoided. This reduces overall complexity and the tendency to promote unwanted side reactions that reduce hydrocarbon yields and lead to CO2 production.

IPC Classes  ?

• C07C 2/76 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen

Abstract

Described herein are methods for stimulating specific groups of neurons in the brain, e.g. the ventral tegmental area (VTA) or its axons, wherein the stimulation can open the blood-brain barrier (BBB) with sub-millimeter and/or sub-second specificity. Stimulation of the VTA can result in opening of the BBB for drug delivery, and/or opening the BBB for clearance of "junk" and/or waste. Also described herein, are non-invasive methods to provide control to BBB permeability.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61N 2/10 - Magnetotherapy using magnetic fields produced by permanent magnets applied within the body, e.g. with injected or implanted elements
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 5/0793 - Neurons

Abstract

A system comprises one or more sensor devices for subcutaneous electroencephalography where each sensor device includes a flexible biocompatible polymer sensor strip adapted to be inserted into a cranial subdermal space and including a plurality of electrodes. The strip includes a microchip responsive to each of the electrodes and comprising a multi-channel integrated circuit system-on-chip with a wireless transceiver, a low-noise neural amplifier, a unique network address, and RF energy harvesting microcircuits. In one embodiment, the sensor strip is no more than about 1 mm wide, at least about 5 cm long, and no more than about 300 μm thick. An external transceiver is disposed on the exterior of the subject's skin near one or more sensor devices in secure wireless communication with the respective wireless transceivers comprised in the sensor devices microchips. The system is configured to communicate using a network communication protocol, such as time division multiple access or code division multiple access.

IPC Classes  ?

• A61B 5/293 - Invasive
• A61B 5/37 - Intracranial electroencephalography [IC-EEG], e.g. electrocorticography [ECoG]
• A61B 5/31 - Input circuits therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]

Abstract

A method of treating malignancy in a subject in need thereof is provided. The method includes administering a therapeutically effective amount of a compound that increases the level of one or more of piR_017723, piR_23656, or piR_016745, or a combination thereof.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method includes, in an automated machine equipped with one or more camera-based object detectors, receiving human-provided information or information inferred from point cloud observations regarding target locations, maintaining information states regarding the target locations through a probability distribution structured as an octree, initializing the information states based on point cloud observations, updating the information states based on object detection observations or point cloud observations, determining a search region occupancy through constructing an octree-based occupancy grid based on point cloud observations, and using ray-tracing to determine visibility at three dimensional locations within the search region.

IPC Classes  ?

• G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
• B25J 9/16 - Programme controls
• G06T 7/70 - Determining position or orientation of objects or cameras
• G06T 15/06 - Ray-tracing

Abstract

Disclosed are pharmaceutical compositions containing micronized antibodies encapsulated and/or dispersed in polymeric particles for antibody delivery. The judicious identification of (i) a subset of polymers, (ii) polymers with certain average molecular weights, (iii) a subset of antibody loadings, and/or (iv) pre-loading antibody processing, leads to formation of polymeric particles that possess minimal to no initial burst release of micronized antibody at zero time point. The pharmaceutical compositions are formulated for oral, subcutaneous, or percutaneous administration, and are particularly suited for treatment regimens that involve antibody-based therapy.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 39/44 - Antibodies bound to carriers
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Goods & Services

Decals; Stationery; Stickers; Desk sets; Folders being stationery; Gift bags; Holders for printed notepads; Office binders; Printed postcards; Writing instruments; Printed notebooks

Abstract

Described herein are methods and compositions for the prevention or treatment of obesity and obesity-related disorders. The methods and compositions are based, inter alia, on the observations that OPN3 is the most highly expressed opsin in the hypothalamus, a key site for the regulation of energy homeostasis. Indeed, OPN3 expression was highest in regions associated with energy homeostasis, namely the paraventricular nucleus and arcuate nucleus of the hypothalamus. OPN3 was shown to interact and form a complex with MC3R and MC4R, and to modulate MC3R- and MC4R-mediated signaling in the hypothalamus. Accordingly, the methods involve the regulation of melanocortin receptors by downregulating opsin 3 (OPN3) protein expression, OPN3 gene expression, and/or OPN3 activation in the hypothalamus.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

TERT plays a crucial role in cancer formation, ensuring chromosomal stability by maintaining telomere length and allowing cells to avoid senescence. Development of telomerase inhibitors has been challenging and thus far there are no clinically approved strategies exploiting this cancer target. Disclosed here is a method to treat cancer using compounds that perform combinatorial targeting of the telomerase and the RNA-dependent RNA polymerase activity of TERT.

IPC Classes  ?

• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61P 35/00 - Antineoplastic agents

Abstract

It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Lanthanide double perovskite nanocrystals are described. The nanocrystals display high energy luminescence, making them useful in a variety of light-emitting materials and devices. Methods of preparing the lanthanide double perovskite nanocrystals using a hot injection method are also described.

IPC Classes  ?

• C09K 11/77 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals
• C01F 17/36 - Compounds containing rare earth metals and at least one element other than a rare earth metal, oxygen or hydrogen, e.g. La4S3Br6 halogen being the only anion, e.g. NaYF4

Abstract

An implantable medical device configured to receive ultrasound energy is provided. The implantable device includes a sonolucent window that is fabricated from a sonolucent material and that is configured to allow US energy to pass therethrough. The medical device can be a bone scaffold. The medical devices can be used for imaging, monitoring, or therapeutic/treatment purposes.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61F 2/28 - Bones

Abstract

A method of treating a neuroendocrine tumor in a subject is described. The method includes determining the level of expression of neuroendocrine differentiation markers and/or TRAIL signaling pathway markers by the tumor, and either treating the subject with a therapeutically effective amount of an imipridone compound if the level of expression of one or more markers is high or treating the subject with a higher dose of the imipridone compound or a different neuroendocrine tumor treatment method.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A photon source for generating entangled photons includes a pump laser, and 4-N, N-dimethylamino-4′-N′-methyl-stilbazolium-tosylate (DAST) crystals, the pump laser pumping the DAST crystals with pump photons to generate a stream of pairs of entangled photons, each pair comprising a signal photon and an idler photon.

IPC Classes  ?

• G02F 1/355 - Non-linear optics characterised by the materials used
• G02F 1/35 - Non-linear optics

Abstract

A method of treating a subject having colon cancer with a small molecule drug for treating colon cancer is described. The method includes determining the effect of the small molecule drug on the release of a plurality of immunomodulating factors by colon cancer cells; and treating the subject with a therapeutically effect amount of the drug if the effect of the drug on the release of immunomodulating factors indicates that the drug promotes anti-tumor immunity, or selecting a different drug for treating colon cancer if the effect of the drug on immunomodulating factor release indicates that the drug does not promote anti-tumor immunity. Methods of evaluating ongoing treatment using the method are also described.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A method of treating cancer, where the biomarkers are predictive of response to PD-1/PD-L1 blockade and GSK-3 inhibition, and which can be used in the method of treatment.

IPC Classes  ?

• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention provides a dual remuscularization-revascularization therapy comprising vascularized engineered human myocardial tissues (vEHMs).

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Described are compositions and methods for treating polyoma viruses such as JCPyV.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61P 31/20 - Antivirals for DNA viruses

Goods & Services

Encouraging intercollegiate athletic programs by organizing and conducting educational programs and activities for intercollegiate athletes and alumni; Organizing and conducting college sport competitions and athletic events; Providing an interactive website featuring advice and information in the field of collegiate athletics programs

Abstract

Methods, systems, and computer programs for identifying a kidney lesion type. In one aspect, the method can include obtaining data that represents an isolated portion of a kidney, providing the obtained data as an input to a machine learning model that has been trained to predict a kidney lesion type based on processing of data representing an isolated portion of a kidney, processing the provided data through each layer of the machine learning model to generate output data indicating a kidney lesion type, obtaining output data generated by the machine learning model based on the machine learning model processing the provided data, and determining a kidney lesion type based on the obtained output data.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06N 3/02 - Neural networks
• G06N 20/00 - Machine learning
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G06T 7/00 - Image analysis

Abstract

The invention provides small-molecule inhibition of GSK-3 to increase efficacy of ICB and improve response in patients with microsatellite stable colorectal cancer, and possibly other tumor types. These results demonstrate 9-ING-41 in combination with αPD-1/PD-L1 therapy.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

MixMix) between the solvent and non-solvent can be tailored to achieve desired particle size, encapsulation efficiency, and release profile.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules

Abstract

A method of reducing toxic side effects in a subject undergoing cancer treatment is described. The method includes administering an effective amount of a TRAIL compound to the subject.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61P 31/04 - Antibacterial agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 35/00 - Antineoplastic agents
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• A61P 3/04 - AnorexiantsAntiobesity agents
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

A method of selecting a recombinant microorganism is described. The method includes providing a genetically modified microorganism that includes an antibiotic selection marker; contacting the genetically modified microorganism with an effective amount of an antibiotic specific for the antibiotic selection marker and an adjuvant; and selecting the genetically modified microorganism by isolating the microorganisms that survive contact with the antibiotic and adjuvant. Methods of identifying novel antibiotic selection markers are also described.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• C12Q 1/24 - Methods of sampling, or inoculating or spreading a sampleMethods of physically isolating an intact microorganism

Goods & Services

Educational services, namely, providing courses of instruction at the university level; Educational services, namely, providing courses of instruction and training in the fields of medicine, biomedical science, and health care policy; Medical training and teaching

Goods & Services

Health care; Home health care services; Hospital services; Medical clinic services; Medical services

Goods & Services

Hospital services; Medical services

Goods & Services

Educational services, namely, providing courses of instruction at the university level; Educational services, namely, providing courses of instruction and training in the fields of medicine, biomedical science, and health care policy; Medical training and teaching